Prior Authorization For Synagis
Human Respiratory Syncytial Virus (RSV) causes respiratory tract infections and serious lung disease in infants and children. Palivizumab (Synagis®) is available with prior authorization for high-risk patients.
The start and end of RSV season in Texas is based on the county of residence. RSV appears earlier in some counties and remains active later in other counties. HHSC uses RSV statistics from prior years plus regular virology reports to determine the season's start and end dates for each region. HHSC reserves the right to extend or end the season after subsequent review of RSV levels in each region.